Cubist Systematic Strategies LLC Buys 76,961 Shares of Astria Therapeutics, Inc. $ATXS

Key Points

• Cubist Systematic Strategies LLC increased its stake in Astria Therapeutics by 503.7%, acquiring an additional 76,961 shares, bringing its total ownership to 92,239 shares valued at $493,000.
• Several other hedge funds also significantly boosted their stakes in Astria Therapeutics, contributing to an overall institutional ownership of 98.98% of the company.
• Astria Therapeutics reported earnings of ($0.57) EPS, which exceeded analysts' expectations, and currently has a consensus rating of "Buy" with an average price target of $29.00.

Cubist Systematic Strategies LLC lifted its stake in shares of Astria Therapeutics, Inc. (NASDAQ:ATXS - Free Report) by 503.7% in the 1st quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 92,239 shares of the biotechnology company's stock after buying an additional 76,961 shares during the period. Cubist Systematic Strategies LLC owned about 0.16% of Astria Therapeutics worth $493,000 as of its most recent SEC filing.

Several other institutional investors also recently modified their holdings of the stock. Vestal Point Capital LP increased its holdings in shares of Astria Therapeutics by 4.5% during the fourth quarter. Vestal Point Capital LP now owns 4,180,000 shares of the biotechnology company's stock worth $37,369,000 after buying an additional 180,000 shares in the last quarter. Northern Trust Corp grew its stake in shares of Astria Therapeutics by 4.5% in the fourth quarter. Northern Trust Corp now owns 458,234 shares of the biotechnology company's stock worth $4,097,000 after purchasing an additional 19,893 shares during the last quarter. Redmile Group LLC grew its stake in shares of Astria Therapeutics by 11.4% in the fourth quarter. Redmile Group LLC now owns 346,278 shares of the biotechnology company's stock worth $3,096,000 after purchasing an additional 35,394 shares during the last quarter. DAFNA Capital Management LLC grew its stake in shares of Astria Therapeutics by 5.0% in the first quarter. DAFNA Capital Management LLC now owns 314,775 shares of the biotechnology company's stock worth $1,681,000 after purchasing an additional 15,000 shares during the last quarter. Finally, Wellington Management Group LLP grew its stake in shares of Astria Therapeutics by 3.1% in the first quarter. Wellington Management Group LLP now owns 152,611 shares of the biotechnology company's stock worth $815,000 after purchasing an additional 4,562 shares during the last quarter. 98.98% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several brokerages recently weighed in on ATXS. JMP Securities boosted their price objective on shares of Astria Therapeutics from $25.00 to $26.00 and gave the stock a "market outperform" rating in a research note on Wednesday, August 13th. Citigroup reissued an "outperform" rating on shares of Astria Therapeutics in a research note on Wednesday, August 13th. Finally, HC Wainwright reissued a "buy" rating and issued a $16.00 price objective on shares of Astria Therapeutics in a research note on Wednesday, August 13th. One equities research analyst has rated the stock with a Strong Buy rating and six have assigned a Buy rating to the stock. According to MarketBeat.com, Astria Therapeutics has a consensus rating of "Buy" and an average price target of $29.00.

Astria Therapeutics Stock Down 5.2%

ATXS traded down $0.41 during trading on Friday, reaching $7.43. 291,955 shares of the stock traded hands, compared to its average volume of 305,956. The stock has a market capitalization of $419.35 million, a PE ratio of -3.70 and a beta of 0.42. The stock's 50-day moving average is $6.69 and its 200 day moving average is $5.72. Astria Therapeutics, Inc. has a 12 month low of $3.56 and a 12 month high of $12.92.

Astria Therapeutics (NASDAQ:ATXS - Get Free Report) last issued its quarterly earnings results on Tuesday, August 12th. The biotechnology company reported ($0.57) EPS for the quarter, beating analysts' consensus estimates of ($0.61) by $0.04. As a group, equities research analysts anticipate that Astria Therapeutics, Inc. will post -1.65 EPS for the current year.

About Astria Therapeutics

Astria Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for allergic and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in Phase 1b/2 clinical trials for the treatment of hereditary angioedema.